Ozempic vs Zepbound 2026: Differences & Which is Better
Ozempic is approved for type 2 diabetes with cardiovascular benefits, while Zepbound is approved specifically for chronic weight management in non-diabetic patients. Both contain semaglutide but are marketed for different primary indications and patient populations.
Ozempic
Semaglutide injection for type 2 diabetes with cardiovascular benefits.
Patients with type 2 diabetes seeking glucose control and cardiovascular protection
Zepbound
Semaglutide injection for chronic weight management in non-diabetic adults.
Non-diabetic patients seeking significant weight loss with cardiovascular risk reduction
Quick Answer
AI SummaryOzempic is approved for type 2 diabetes with cardiovascular benefits, while Zepbound is approved specifically for chronic weight management in non-diabetic patients. Both contain semaglutide but are marketed for different primary indications and patient populations.
Our Verdict
AI-assistedChoose Ozempic if you have type 2 diabetes and need proven cardiovascular protection alongside glucose control—it has the strongest evidence for reducing heart attack and stroke risk. Choose Zepbound if you're seeking weight management without diabetes and prioritize maximum weight loss; however, expect higher out-of-pocket costs since insurance coverage is limited for non-diabetic use.
Was this verdict helpful?
Choose Ozempic if
Patients with type 2 diabetes seeking glucose control and cardiovascular protection
Choose Zepbound if
Best pickNon-diabetic patients seeking significant weight loss with cardiovascular risk reduction
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Primary FDA Approval:Type 2 diabetes (2017) vs Chronic weight management (2023)
- Active Ingredient:Semaglutide 0.25-2.4 mg vs Semaglutide 0.25-2.4 mg
- Average Weight Loss (16 weeks):✓ Zepbound wins(15-22 lbs in non-diabetic patients vs 5-8 lbs in diabetic patients)
Key Facts & Figures
36 numeric metrics compared
| Metric | Ozempic | Zepbound | Ratio |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| FDA Approval Year | 2017 | — | — |
| Number of Dose Strengths Available(strengths) | 4 | — | — |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | — | — |
| FDA Approval Year(year) | 2017 (diabetes) | — | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | — | — |
| Injection Frequency(times per week) | 1 | — | — |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | — | — |
| Time to Maintenance Dose(weeks) | 12 | — | — |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | — | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — | — |
| Injection Schedule(per week) | Once weekly | — | — |
| Average Retail Price(USD/month) | $900-1,300 | — | — |
| Number of Dose Strengths Available(options) | 3 | — | — |
| Time on Market(years) | 9 years | — | — |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | — | — |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | — | — |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | — | — |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | — | — |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | — | — |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | — | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | — | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 5-7% (diabetes indication) | — | — |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | — | — |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | — | — |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | — | — |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — | — |
| Average Weight Loss at 16 Weeks(lbs) | 5-8 lbs (diabetic patients) | 15-22 lbs (non-diabetic patients) | |
| Cardiovascular Event Risk Reduction(%) | 26% (SUSTAIN-6 trial, n=3,297) | 20% (SELECT trial, n=17,604) | |
| Nausea Incidence Rate(%) | 40% at 1.0 mg dose | 25-35% at maintenance dose | |
| Average Out-of-Pocket Monthly Cost(USD) | $50-150 (with diabetes insurance) | $300-400 (limited insurance coverage) | |
| HbA1c Reduction(percentage points) | 1.5-2.0 points | Not primary endpoint | — |
| Clinical Trial Sample Size(participants) | 3,297 (SUSTAIN-6) | 17,604 (SELECT) |
Sourced from publicly available data ·
Key Differences
7 attributes compared head-to-head
- Type 2 diabetes (2017)Primary FDA ApprovalChronic weight management (2023)
- Semaglutide 0.25-2.4 mgActive IngredientSemaglutide 0.25-2.4 mg
- 5-8 lbs in diabetic patientsAverage Weight Loss (16 weeks)15-22 lbs in non-diabetic patients(winner)
- 26% reduction (SUSTAIN-6 trial)(winner)Cardiovascular Event Reduction20% reduction (SELECT trial)
- 0.25 mg weeklyStarting Dose0.25 mg weekly
- Not typically covered for weight loss only(winner)Insurance Coverage for Weight LossLimited coverage; mostly out-of-pocket
- 2.4 mg weeklyApproved Maximum Dose2.4 mg weekly
- Primary FDA Approval
Ozempic
Type 2 diabetes (2017)
Zepbound
Chronic weight management (2023)
- Active Ingredient
Ozempic
Semaglutide 0.25-2.4 mg
Zepbound
Semaglutide 0.25-2.4 mg
- Average Weight Loss (16 weeks)
Ozempic
5-8 lbs in diabetic patients
Zepbound
15-22 lbs in non-diabetic patients(winner)
- Cardiovascular Event Reduction
Ozempic
26% reduction (SUSTAIN-6 trial)(winner)
Zepbound
20% reduction (SELECT trial)
- Starting Dose
Ozempic
0.25 mg weekly
Zepbound
0.25 mg weekly
- Insurance Coverage for Weight Loss
Ozempic
Not typically covered for weight loss only(winner)
Zepbound
Limited coverage; mostly out-of-pocket
- Approved Maximum Dose
Ozempic
2.4 mg weekly
Zepbound
2.4 mg weekly
Full Comparison
| Attribute | Ozempic | Zepbound |
|---|---|---|
| Average Weight Loss(%) | 8-12% | — |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | — |
| A1C Reduction(percentage points) | 1.5-2.0% | — |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | — |
Show 2 more attributesAverage Weight Loss (Clinical Trial)(% body weight) 5-7% (diabetes indication) — Average Weight Loss at 16 Weeks(lbs) 5-8 lbs (diabetic patients) 15-22 lbs (non-diabetic patients) | ||
| Monthly Cost (without insurance)(USD) | ~$900 | — |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | — |
| Average Retail Price(USD/month) | $900-1,300 | — |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | — |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | — |
Show 1 more attributeAverage Out-of-Pocket Monthly Cost(USD) $50-150 (with diabetes insurance) $300-400 (limited insurance coverage) | ||
| Active Ingredient | Semaglutide | — |
| Active Pharmaceutical Ingredient | Semaglutide (recombinant human GLP-1 analog) | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | — |
| Active Ingredient Concentration Range(mg) | 0.25-2.4 mg weekly injection | 0.25-2.4 mg weekly injection |
| FDA Approval Year | 2017 | — |
| FDA Approval Year(year) | 2017 (diabetes) | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | — |
| FDA Approval Date | December 2017 | November 2023 |
| Primary Indication | Type 2 Diabetes | — |
| Cardiovascular Benefits | Proven in diabetic patients | — |
| Typical Insurance Coverage | Widely covered for diabetes | — |
| Number of Dose Strengths Available(strengths) | 4 | — |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | — |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | — |
| Injection Frequency(times per week) | 1 | — |
| Injection Schedule(per week) | Once weekly | — |
| Injection Frequency(times per week) | Once weekly subcutaneous injection | — |
| Time to Maintenance Dose(weeks) | 12 | — |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | — |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | — |
| Number of Dose Strengths Available(options) | 3 | — |
| Time on Market(years) | 9 years | — |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | — |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | — |
| Cardiovascular Event Risk Reduction(%) | 26% (SUSTAIN-6 trial, n=3,297)(winner) | 20% (SELECT trial, n=17,604) |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | — |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | — |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — |
| Nausea Incidence Rate(%) | 40% at 1.0 mg dose | 25-35% at maintenance dose(winner) |
| HbA1c Reduction(percentage points) | 1.5-2.0 points | Not primary endpoint |
| Clinical Trial Sample Size(participants) | 3,297 (SUSTAIN-6) | 17,604 (SELECT)(winner) |
OzempicZepboundShow 2 more attributes
Show 1 more attribute
Pros & Cons
10 pros·4 cons across both
Ozempic
Pros
- 26% reduction in major cardiovascular events (SUSTAIN-6 trial, 2016)
- Better insurance coverage when prescribed for diabetes
- Established safety data from 7+ years of clinical use
- Lowers HbA1c by 1.5-2.0 percentage points on average
- GLP-1 mechanism reduces cardiovascular and renal disease risk
Cons
- Average weight loss of only 5-8 lbs in diabetic patients
- Higher gastrointestinal side effects (nausea 40%, vomiting 15%) in early studies
Zepbound
Pros
- Average weight loss of 15-22 lbs in 16 weeks (SELECT trial data)
- Approved for non-diabetic chronic weight management
- 20% reduction in cardiovascular events in non-diabetic overweight/obese patients
- Same proven semaglutide mechanism as Ozempic
- Higher efficacy in weight reduction compared to diabetes formulation
Cons
- Limited insurance coverage; typically requires out-of-pocket payment ($300-$400/month)
- Gastrointestinal side effects (nausea 25-35%, diarrhea 20%) reported in trials
Frequently Asked Questions
5 questions
Yes and no. Both contain identical active ingredient (semaglutide) at the same doses (0.25-2.4 mg weekly), but they are branded and approved for different indications. Ozempic is FDA-approved for type 2 diabetes since 2017, while Zepbound is FDA-approved specifically for chronic weight management since 2023. Using Ozempic off-label for weight loss is common but not its primary indication.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
Related Comparisons
12 more to explore
Ozempic vs Wegovy
healthOzempic vs Mounjaro
healthOzempic vs Wegovy
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthTherapy vs Medication
healthMeditation vs Yoga
healthContact Lenses vs Glasses
healthPhysical Therapy vs Chiropractic
health
Related Articles
1 article
Explore More
Related comparisons and categories